AAAAAA

   
Results: 1-25 | 26-30
Results: 1-25/30
IL-2 PLUS G-CSF AS A MOBILIZATION REGIMEN IN ADVANCED BREAST-CANCER PATIENTS RECEIVING HIGH-DOSE CHEMOTHERAPY - MARKED EXPANSION OF ACTIVATED T AND NK CELLS WITH ENHANCED CYTOLYTIC ACTIVITY WITHIN THE AUTOGRAFT, WITHOUT COMPROMISE OF ME HEMATOLOGIC ENGRAFTMENT
Authors: SOSMAN J MOSS ST SOROKIN P MARTONE B DEVINE S PEACE D STOCK W HOFFMAN R STIFF P THOMASON D WICKREMA A AMIN K VANBESIEN K
Citation: J. Sosman et al., IL-2 PLUS G-CSF AS A MOBILIZATION REGIMEN IN ADVANCED BREAST-CANCER PATIENTS RECEIVING HIGH-DOSE CHEMOTHERAPY - MARKED EXPANSION OF ACTIVATED T AND NK CELLS WITH ENHANCED CYTOLYTIC ACTIVITY WITHIN THE AUTOGRAFT, WITHOUT COMPROMISE OF ME HEMATOLOGIC ENGRAFTMENT, Experimental hematology, 26(8), 1998, pp. 321-321
SUCCESSFUL AUTOTRANSPLANTATION OF EX-VIVO EXPANDED SMALL BONE-MARROW ALIQUOTS IN PATIENTS WITH BREAST-CANCER USING PERFUSION BIOREACTORS
Authors: STIFF P OLDENBERG D HSI E CHEN B SMITH A ARMSTRONG RD MULLER T
Citation: P. Stiff et al., SUCCESSFUL AUTOTRANSPLANTATION OF EX-VIVO EXPANDED SMALL BONE-MARROW ALIQUOTS IN PATIENTS WITH BREAST-CANCER USING PERFUSION BIOREACTORS, Bone marrow transplantation, 21, 1998, pp. 207-207
A PHASE-II TRIAL OF INTERLEUKIN-2 IN MYELODYSPLASTIC SYNDROMES
Authors: NAND S STOCK W STIFF P SOSMAN J MARTONE B RADVANY R
Citation: S. Nand et al., A PHASE-II TRIAL OF INTERLEUKIN-2 IN MYELODYSPLASTIC SYNDROMES, British Journal of Haematology, 101(1), 1998, pp. 205-207
A FOOTNOTE KICKS HIM - HOW BOOKS MAKE READERS WORK
Authors: STIFF P
Citation: P. Stiff, A FOOTNOTE KICKS HIM - HOW BOOKS MAKE READERS WORK, Journal of scholarly publishing, 28(2), 1997, pp. 65-73
BMT PATIENTS RECEIVING PROPHYLACTIC ENTERAL SUPPORT HAVE REDUCED LENGTH OF HOSPITAL STAY, IMPROVED GI INTEGRITY AND NUTRITIONAL-STATUS, ANDREDUCED INTAKE REQUIREMENTS REQUIRED FOR POSITIVE OUTCOME
Authors: DEMEO M COPE FO STIFF P ROONEY D ATAYA D HRUSHESKY W HOLMES E MCCAMISH M KESHAVARZIAN A
Citation: M. Demeo et al., BMT PATIENTS RECEIVING PROPHYLACTIC ENTERAL SUPPORT HAVE REDUCED LENGTH OF HOSPITAL STAY, IMPROVED GI INTEGRITY AND NUTRITIONAL-STATUS, ANDREDUCED INTAKE REQUIREMENTS REQUIRED FOR POSITIVE OUTCOME, The FASEB journal, 11(3), 1997, pp. 3340-3340
USE OF STEM-CELL FACTOR PLUS FILGRASTIM IMPROVES PBPC COLLECTION IN HEAVILY PRETREATED PATIENTS WITH LYMPHOMA OR HODGKINS-DISEASE
Authors: STIFF P EMMANOUILIDES C LUGER S HARMAN G LEMAISTRE CF BROWN R PERRY J MASON JR LIST A BENSINGER W FRETER D SCHENKEIN D BRANNAN C OLSON E WYRES M WHEELER C
Citation: P. Stiff et al., USE OF STEM-CELL FACTOR PLUS FILGRASTIM IMPROVES PBPC COLLECTION IN HEAVILY PRETREATED PATIENTS WITH LYMPHOMA OR HODGKINS-DISEASE, Experimental hematology, 25(8), 1997, pp. 359-359
A PHASE-II STUDY OF INTERLEUKIN-2 IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
Authors: NAND S STOCK W STIFF P SOSMAN J MARTONE B RADVANY R
Citation: S. Nand et al., A PHASE-II STUDY OF INTERLEUKIN-2 IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES, Blood, 90(10), 1997, pp. 4046-4046
RANDOMIZED TRIAL OF A SHORT-COURSE OF G-CSF TO PRIME BONE-MARROW FOR INCREASED STEM-CELL COLLECTION IN NORMAL VOLUNTEERS
Authors: MALHOTRA D CHEN B HSI E KERGER C OLDENBERG D BAYER R STIFF P
Citation: D. Malhotra et al., RANDOMIZED TRIAL OF A SHORT-COURSE OF G-CSF TO PRIME BONE-MARROW FOR INCREASED STEM-CELL COLLECTION IN NORMAL VOLUNTEERS, Blood, 90(10), 1997, pp. 4236-4236
A PHASE-III STUDY EVALUATING CD34(-BLOOD PROGENITOR-CELL TRANSPLANTATION FOR PATIENTS WITH ADVANCED MULTIPLE-MYELOMA - ENGRAFTMENT RESULTS() SELECTED VERSUS UNSELECTED AUTOLOGOUS PERIPHERAL)
Authors: SCHILLER G STEWART AK BALLESTER O NOGA S RUGO H FREYTES C STADTMAUER E KOGUT N TARANFOLO S STIFF P PINEIRO L DALTON W HO A VESCIO R BENYUNES M JACOBS C DIPERSIO J ANDERSON K BERENSON J
Citation: G. Schiller et al., A PHASE-III STUDY EVALUATING CD34(-BLOOD PROGENITOR-CELL TRANSPLANTATION FOR PATIENTS WITH ADVANCED MULTIPLE-MYELOMA - ENGRAFTMENT RESULTS() SELECTED VERSUS UNSELECTED AUTOLOGOUS PERIPHERAL), Blood, 90(10), 1997, pp. 960-960
A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL OF INFUSIONAL OCTREOTIDE IN THE TREATMENT OF SEVERE DIARRHEA CAUSED BY HIGH-DOSE TRANSPLANT REGIMENS
Authors: ANDREY J SEGUIERA E STIFF P BAYER R MALHOTRA D PORTER N KILEY K FISHER S
Citation: J. Andrey et al., A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL OF INFUSIONAL OCTREOTIDE IN THE TREATMENT OF SEVERE DIARRHEA CAUSED BY HIGH-DOSE TRANSPLANT REGIMENS, Blood, 90(10), 1997, pp. 978-978
TRANSPLANTATION OF EX-VIVO EXPANDED CELLS GROWN IN AASTROM STROMAL-BASED PERFUSION BIOREACTORS FROM SMALL MARROW ALIQUOTS (40 ML) PRODUCES DURABLE HEMATOPOIETIC RECONSTITUTION AFTER ABLATIVE CHEMOTHERAPY
Authors: STIFF P OLDENBERG D HSI E CHEN B SMITH A BAYER R MALHOTRA D KERGER C ARMSTRONG RD MULLER T
Citation: P. Stiff et al., TRANSPLANTATION OF EX-VIVO EXPANDED CELLS GROWN IN AASTROM STROMAL-BASED PERFUSION BIOREACTORS FROM SMALL MARROW ALIQUOTS (40 ML) PRODUCES DURABLE HEMATOPOIETIC RECONSTITUTION AFTER ABLATIVE CHEMOTHERAPY, Blood, 90(10), 1997, pp. 1755-1755
MYELOMA CELL TUMOR REDUCTION IN PBPC AUTOGRAFTS FOLLOWING CD34 SELECTION - THE RESULTS OF A PHASE-III TRIAL USING THE CEPRATE DEVICE
Authors: VESCIO R STEWART A BALLESTER O NOGA S RUGO H FREYTES C STADTMAUER E KOGUT N TARANTOLO S STIFF P PINERO L DALTON W HO A SCHILLER G BENYUNES M JACOBS C DIPERSIO J ANDERSON K BERENSON J
Citation: R. Vescio et al., MYELOMA CELL TUMOR REDUCTION IN PBPC AUTOGRAFTS FOLLOWING CD34 SELECTION - THE RESULTS OF A PHASE-III TRIAL USING THE CEPRATE DEVICE, Blood, 90(10), 1997, pp. 1872-1872
INCREASE IN CIRCULATING TUMOR-CELL BURDEN DURING MOBILIZATION CHEMOTHERAPY PREDICTS FOR RELAPSE AFTER AUTOLOGOUS TRANSPLANTATION IN MULTIPLE-MYELOMA PATIENTS
Authors: VESCIO R STEWART A BALLESTER O NOGA S RUGO H FREYTES C STADTMAUER E KOGUT N TARANTOLO S STIFF P PINERO L DALTON W HO A SCHILLER G BENYUNES M JACOBS C DIPERSIO J ANDERSON K BERENSON J
Citation: R. Vescio et al., INCREASE IN CIRCULATING TUMOR-CELL BURDEN DURING MOBILIZATION CHEMOTHERAPY PREDICTS FOR RELAPSE AFTER AUTOLOGOUS TRANSPLANTATION IN MULTIPLE-MYELOMA PATIENTS, Blood, 90(10), 1997, pp. 2515-2515
THE DETECTION OF KSHV IS INCREASED BY MOBILIZATION CHEMOTHERAPY AND REDUCED IN AUTOGRAFTS BY CD34-SELECTION
Authors: VESCIO R WU C RETTIG M STEWART A BALLESTER O NOGA S RUGO H FREYTES C STADTMAUER E KOGUT N TARANTOLO S STIFF P PINERO L DALTON W HO A SCHILLER G BENYUNES M JACOBS C DIPERSIO J ANDERSON K BERENSON J
Citation: R. Vescio et al., THE DETECTION OF KSHV IS INCREASED BY MOBILIZATION CHEMOTHERAPY AND REDUCED IN AUTOGRAFTS BY CD34-SELECTION, Blood, 90(10), 1997, pp. 2516-2516
IMPROVED PBPC COLLECTION USING STEMGEN(R) (STEM-CELL FACTOR, SCF) ANDFILGRASTIM (G-CSF) COMPARED TO G-CSF ALONE IN HEAVILY PRETREATED LYMPHOMA (NNL) AND HODGKINS-DISEASE (HD) PATIENTS (PTS)
Authors: STIFF P GINGRICH R LUGER S BROWN RA LEMAISTRE CF PERRY J SCHENKEIN D LIST A MASON JR BENSINGER W WHEELER CA FRETER C MURPHYFILKINS R WYRES M PARKER W EMMANOUILIDES C
Citation: P. Stiff et al., IMPROVED PBPC COLLECTION USING STEMGEN(R) (STEM-CELL FACTOR, SCF) ANDFILGRASTIM (G-CSF) COMPARED TO G-CSF ALONE IN HEAVILY PRETREATED LYMPHOMA (NNL) AND HODGKINS-DISEASE (HD) PATIENTS (PTS), Blood, 90(10), 1997, pp. 2628-2628
HIGH-DOSE G-CSF IMPROVES STEM-CELL MOBILIZATION AND COLLECTION COMPARED TO STANDARD DOSES IN PATIENTS WITH OVARIAN-CANCER WHICH LEADS TO A DECREASE IN DELAYED PLATELET ENGRAFTMENT FOLLOWING STEM-CELL TRANSPLANTS
Authors: STIFF P MALHOTRA D BAYER R PODIAK M KERGER C
Citation: P. Stiff et al., HIGH-DOSE G-CSF IMPROVES STEM-CELL MOBILIZATION AND COLLECTION COMPARED TO STANDARD DOSES IN PATIENTS WITH OVARIAN-CANCER WHICH LEADS TO A DECREASE IN DELAYED PLATELET ENGRAFTMENT FOLLOWING STEM-CELL TRANSPLANTS, Blood, 90(10), 1997, pp. 2629-2629
RECOMBINANT METHIONYL HUMAN STEM-CELL FACTOR AND FILGRASTIM FOR PERIPHERAL-BLOOD PROGENITOR-CELL MOBILIZATION AND TRANSPLANTATION IN NON-HODGKINS-LYMPHOMA PATIENTS - RESULTS OF A PHASE I II TRIAL/
Authors: MOSKOWITZ CH STIFF P GORDON MS MCNIECE I HO AD COSTA JJ BROUN ER BAYER RA WYRES M HILL J JELACAMAXWELL K NICHOLS CR BROWN SL NIMER SD GABRILOVE J
Citation: Ch. Moskowitz et al., RECOMBINANT METHIONYL HUMAN STEM-CELL FACTOR AND FILGRASTIM FOR PERIPHERAL-BLOOD PROGENITOR-CELL MOBILIZATION AND TRANSPLANTATION IN NON-HODGKINS-LYMPHOMA PATIENTS - RESULTS OF A PHASE I II TRIAL/, Blood, 89(9), 1997, pp. 3136-3147
ALL-TRANS-RETINOIC ACID, LOW-DOSE CYTOSINE-ARABINOSIDE AND GRANULOCYTE-COLONY-STIMULATING FACTOR IN ACUTE MYELOGENOUS LEUKEMIA - UPDATE OF AN ILLINOIS CANCER CENTER PHASE-II PILOT-STUDY
Authors: TALLMAN MS MILLER HJ ZANZIG C RADEMAKER A GORDON L HAKIMIAN D VARIAKOJIS D STIFF P FRENCH S BENSON AB
Citation: Ms. Tallman et al., ALL-TRANS-RETINOIC ACID, LOW-DOSE CYTOSINE-ARABINOSIDE AND GRANULOCYTE-COLONY-STIMULATING FACTOR IN ACUTE MYELOGENOUS LEUKEMIA - UPDATE OF AN ILLINOIS CANCER CENTER PHASE-II PILOT-STUDY, Experimental hematology, 24(9), 1996, pp. 549-549
LISOFYLLINE (LSF) REDUCES INFECTION-RATE AND IMPROVES SURVIVAL IN PTSUNDERGOING ALLOGENIC BONE-MARROW TRANSPLANTATION (BMT) - RESULTS OF ARANDOMIZED, PLACEBO-CONTROLLED TRIAL
Authors: LIST A MAZIARZ R STIFF P JANSEN J LIESFELD J SCHUSTER M ANDREWS DF KARANES I WOLF S LITZOW M
Citation: A. List et al., LISOFYLLINE (LSF) REDUCES INFECTION-RATE AND IMPROVES SURVIVAL IN PTSUNDERGOING ALLOGENIC BONE-MARROW TRANSPLANTATION (BMT) - RESULTS OF ARANDOMIZED, PLACEBO-CONTROLLED TRIAL, Blood, 88(10), 1996, pp. 1825-1825
PHASE-I STUDY OF THE CHEMOSENSITIZER SDZ PSC-833 IN COMBINATION WITH VAD CHEMOTHERAPY TO REVERSE MULTIDRUG-RESISTANCE
Authors: DALTON W GREIPP P GREENBERG P STIFF P BALLESTER O FRIEDENBERG W SALMON S KYLE R CHARNICK S PEARCE T
Citation: W. Dalton et al., PHASE-I STUDY OF THE CHEMOSENSITIZER SDZ PSC-833 IN COMBINATION WITH VAD CHEMOTHERAPY TO REVERSE MULTIDRUG-RESISTANCE, Blood, 88(10), 1996, pp. 2638-2638
RESTING ENERGY-EXPENDITURE (REE) AFTER HIGH-DOSE THERAPY (HDT) AND BONE-MARROW TRANSPLANTATION (BMT)
Authors: KAZI N DEMEO M KRUGER A STIFF P KESHAVARZIAN A MOBARHAN S
Citation: N. Kazi et al., RESTING ENERGY-EXPENDITURE (REE) AFTER HIGH-DOSE THERAPY (HDT) AND BONE-MARROW TRANSPLANTATION (BMT), The FASEB journal, 9(4), 1995, pp. 992-992
A PHASE-II TRIAL OF HIGH-DOSE MITOXANTRONE, CARBOPLATIN, AND CYCLOPHOSPHAMIDE WITH AUTOLOGOUS BONE-MARROW RESCUE FOR RECURRENT EPITHELIAL OVARIAN-CARCINOMA - ANALYSIS OF RISK-FACTORS FOR CLINICAL OUTCOME
Authors: STIFF P BAYER R CAMARDA M TAN S DOLAN J POTKUL R LOUTFI S KINCH L SOSMAN J PEACE D RAD N MCKENZIE RS
Citation: P. Stiff et al., A PHASE-II TRIAL OF HIGH-DOSE MITOXANTRONE, CARBOPLATIN, AND CYCLOPHOSPHAMIDE WITH AUTOLOGOUS BONE-MARROW RESCUE FOR RECURRENT EPITHELIAL OVARIAN-CARCINOMA - ANALYSIS OF RISK-FACTORS FOR CLINICAL OUTCOME, Gynecologic oncology, 57(3), 1995, pp. 278-285
HIGH-DOSE CHEMOTHERAPY AND RADIOTHERAPY (HDCR) BEFORE BONE-MARROW TRANSPLANTATION (BMT) RESULTS IN SELECTIVE LOSS OF INTEGRITY OF SMALL-INTESTINAL (SI) BUT NOT GASTRODUODENAL (GD) MUCOSA - BENEFICIAL-EFFECTS OF ENTERAL NUTRITION (EN)
Authors: KAZI N HOLMES E DEMEO M KRUGER A OLDHAM T STIFF P MOBARHAN S KESHAVARZIAN A
Citation: N. Kazi et al., HIGH-DOSE CHEMOTHERAPY AND RADIOTHERAPY (HDCR) BEFORE BONE-MARROW TRANSPLANTATION (BMT) RESULTS IN SELECTIVE LOSS OF INTEGRITY OF SMALL-INTESTINAL (SI) BUT NOT GASTRODUODENAL (GD) MUCOSA - BENEFICIAL-EFFECTS OF ENTERAL NUTRITION (EN), Gastroenterology, 108(4), 1995, pp. 733-733
SEQUENTIAL ADMINISTRATION OF RECOMBINANT HUMAN INTERLEUKIN-3 (IL-3) AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) THERAPY FOR LYMPHOMA - RESULTS OF A PHASE-III MULTICENTER STUDY
Authors: FAY JW FELSER JM ABBOUD C BORSON R FREYTES C HERZIG R HURD D JANAKIRAMAN N JANSEN J LAZARUS H LYNCH JP MANGAN KF SAEZ R STEVENS DA WOLFF SN YANOVICH S STIFF P
Citation: Jw. Fay et al., SEQUENTIAL ADMINISTRATION OF RECOMBINANT HUMAN INTERLEUKIN-3 (IL-3) AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) THERAPY FOR LYMPHOMA - RESULTS OF A PHASE-III MULTICENTER STUDY, Blood, 86(10), 1995, pp. 875-875
THE INFLUENCE OF EXTENSIVE PRIOR CHEMOTHERAPY ON THE MOBILIZATION OF PERIPHERAL-BLOOD PROGENITOR CELLS (PBPC) USING STEM-CELL FACTOR (RHSCF) AND FILGRASTIM (RMETHUG-SCF) AND ON HEMATOLOGIC RECOVERY POST CYCLOPHOSPHAMIDE, BCNU, AND VP-16 (CBV) IN PATIENTS (PTS) WITH RELAPSED NON-HODGKINS-LYMPHOMA (NHL) - AN INTERIM ANALYSIS
Authors: MOSKOWITZ C STIFF P GORDON M GABRILOVE J BAYER R BROUN R NICHOLS C HO AD WYRES M NIMER S MCNIECE I
Citation: C. Moskowitz et al., THE INFLUENCE OF EXTENSIVE PRIOR CHEMOTHERAPY ON THE MOBILIZATION OF PERIPHERAL-BLOOD PROGENITOR CELLS (PBPC) USING STEM-CELL FACTOR (RHSCF) AND FILGRASTIM (RMETHUG-SCF) AND ON HEMATOLOGIC RECOVERY POST CYCLOPHOSPHAMIDE, BCNU, AND VP-16 (CBV) IN PATIENTS (PTS) WITH RELAPSED NON-HODGKINS-LYMPHOMA (NHL) - AN INTERIM ANALYSIS, Blood, 84(10), 1994, pp. 10000107-10000107
Risultati: 1-25 | 26-30